Pfizer (PFE) Xalkori publishes positive result for lung cancer patients
Pfizer Inc. (NYSE: PFE) reported that an experiment showed its lung cancer drug Xalkori markedly improved progression-free endurance in previously treated patients with anaplastic lymphoma kinase-positive complex non-small cell lung cancer.
In August, the US Food and Drug Administration accepted Xalkori, also known as crizotinib, as a cure for ALK-positive patients with advanced NSCLC. Pfizer also began marketing the capsules in Japan last month.
The drug company reported that its study looked at Profile 1007 Xalkori with the chemotherapy drugs pemetrexed and docetaxel.
Its competitors include Merck & Co., Inc. (NYSE: MRK), which rose 1.00% to $ 39.24 with a total trading volume of 2.43 million shares, and Novartis AG (ADR) (NYSE: NVS) ) with a total traded volume of 923,876.00 shares.
Other uptrending healthcare stocks include Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), which rose 5.65% to $ 9.91, Johnson & Johnson (NYSE: JNJ), which rose 0.63% to 66, $ 72 and Boston Scientific Corporation (NYSE: BSX) up 1.99% to $ 5.89 5, while CEL-SCI Corporation (NYSEAMEX: CVM) declined by -15.34% to $ 0.347 , Dendreon Corporation (NASDAQ: DNDN) were down -4.79% to $ 7.16, and Genetic Technologies Limited (ADR) (NASDAQ: GENE) were down $ 3.29% to $ 4.11.
Pfizer Inc. (NYSE: PFE) hit a high of $ 22.80 after opening at $ 22.72 and then traded at $ 22.80, rising 0.80% at 10:52 a.m. EDT, and the current session volume of 4.63 million shares is surprisingly lower than its average volume of 34.76 million shares.
The stock price volatility was 1.58% for a week and 1.47% for a month, and the Average True Range of price volatility for 14 days was 0.35 and the beta stayed at 0.71.
The liquidity ratio in the company’s last quarter results was 2.02 as the current ratio and on the other hand, the debt to equity ratio was 0.47 and the long-term debt to equity ratio also remained 0.40. The company had total cash on hand for the last quarter of $ 23.99 billion and a book value per share of $ 11.11.
PFE had sales of $ 66.33 billion and earned $ 8.28 billion for the next twelve months. The company posted a positive 12.54% in net profit margin and operating margin, which remained 18.39%. The company’s annual revenue growth over the past five years has been 6.87%.